on Nanohale AG (ETR:FYB)
Ranibizumab Biosimilar Epruvy® Launched in Germany
Sandoz has introduced Epruvy® in Germany, available in innovative pre-filled syringe (PFS) and vial formats, under a license from Bioeq AG. This launch marks a notable progression in the availability of ranibizumab biosimilars, offering broader access for treating visual impairments such as neovascular age-related macular degeneration (nAMD).
Approved by the European Medicines Agency in 2024, Epruvy® is designed for silicone-free intravitreal injections. This ensures high dosing accuracy and low injection pressure, reducing potential application errors. The convenience of ready-to-use syringes supports efficient administration, benefiting patients and healthcare providers alike.
Nicola Mikulcik, CBO of Formycon, highlights this launch as a significant step towards enhancing Epruvy®'s market penetration, providing improved ophthalmic care in Germany. This development sets the stage for wider adoption in major healthcare markets in Europe.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Nanohale AG news